AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Dr. Jin Wang as Site Head/General Manager of its Bothell operations.

Ms. Wang will provide leadership and site management to ensure AGC Biologics’ continued execution of world-class contract development and manufacturing services. Dr. Wang will report to Patricio Massera, Chief Operations Officer.

Dr. Wang brings more than 20 years of leadership experience in the biotechnology and manufacturing industry, most recently serving as Site Head of Bacterial Vaccine Manufacturing, Global Vaccines Industrial Affairs with Sanofi Group in Swiftwater, PA. In this role she was responsible for leading and driving manufacturing processes and building operational leadership capability, as the organization provided meningococcal vaccine supplies to the United States and more than 68 international countries.

During her tenure with Sanofi, Dr. Wang also served as Project Director for Global Manufacturing Technology out of its Toronto, Canada location, Head of its multiproduct manufacturing facility for the launch of the SAR34103 Biosimilar mAb, and Head of its single-use technology-based facility for the commercialization of Cdiffense.

Prior to Sanofi, Dr. Wang held leadership roles within multiple organizations including Bayer HealthCare, the Schering-Plough Research Institute, ImClone Systems, and Covance Biotechnology Services.

“The role of Site Head/General Manager in our Bothell, Washington facility — AGC Biologics’ global headquarters — is critical to our operations expansion and growth,” said Patricio Massera, AGC Biologics chief operations officer in a press release. “Dr. Wang’s expertise and experience in biologics and strong leadership skills are the perfect combination to lead the Bothell site into the future.”